

Detection of oligomeric forms of α -synuclein protein biomarker for Parkinson's disease

FASEB Journal

20, 419-425

DOI: [10.1096/fj.03-1449com](https://doi.org/10.1096/fj.03-1449com)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 967-972.	1.0	175
2	Decreased α -synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 162-166.	1.0	386
3	Diagnosis and treatment of Parkinson disease: molecules to medicine. <i>Journal of Clinical Investigation</i> , 2006, 116, 1744-1754.	3.9	538
4	Autoantibodies to alpha-synuclein in inherited Parkinson's disease. <i>Journal of Neurochemistry</i> , 2006, 101, 749-756.	2.1	161
5	Inhibitors of α -synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. <i>Experimental Brain Research</i> , 2006, 173, 223-233.	0.7	59
6	Different Species of α -Synuclein Oligomers Induce Calcium Influx and Seeding. <i>Journal of Neuroscience</i> , 2007, 27, 9220-9232.	1.7	708
7	Translating Genetic Findings into Therapy in Parkinson Disease. <i>Recent Patents on CNS Drug Discovery</i> , 2007, 2, 229-237.	0.9	0
8	Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. <i>Neurology</i> , 2007, 69, 2093-2104.	1.5	191
9	DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers. <i>Neurology</i> , 2007, 68, 812-819.	1.5	515
10	Identification of Novel Proteins Associated with Both α -Synuclein and DJ-1. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 845-859.	2.5	153
11	Impact of recent genetic findings in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2007, 20, 453-464.	1.8	93
13	Chapter 8 α -Synuclein and Synucleinopathies. <i>Blue Books of Neurology</i> , 2007, 30, 186-215.	0.1	4
14	Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α -synuclein fibril formation in vitro. <i>Experimental Neurology</i> , 2007, 203, 579-583.	2.0	12
15	Plasma α -synuclein is decreased in subjects with Parkinson's disease. <i>Experimental Neurology</i> , 2007, 204, 583-588.	2.0	140
16	Isolation of a Human Single Chain Antibody Fragment Against Oligomeric α -Synuclein that Inhibits Aggregation and Prevents α -Synuclein-induced Toxicity. <i>Journal of Molecular Biology</i> , 2007, 368, 1132-1144.	2.0	143
17	Sensitive ELISA detection of amyloid β 2 protofibrils in biological samples. <i>Journal of Neurochemistry</i> , 2007, 103, 334-345.	2.1	174
18	Sensitive Fluorescence Polarization Technique for Rapid Screening of α -Synuclein Oligomerization/Fibrillization Inhibitors. <i>Biochemistry</i> , 2007, 46, 12522-12529.	1.2	46
19	Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. , 2007, , 91-104.		66

#	ARTICLE	IF	CITATIONS
20	Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. Expert Review of Neurotherapeutics, 2007, 7, 1693-1729.	1.4	17
21	Î³-synuclein and the progression of cancer. FASEB Journal, 2007, 21, 3419-3430.	0.2	94
22	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Movement Disorders, 2007, 22, 1481-1484.	2.2	103
23	An investigation into the lipid-binding properties of Î±-, Î²- and Î³-synucleins in human brain and cerebrospinal fluid. Brain Research, 2007, 1170, 103-111.	1.1	8
24	Development of Î±-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathologica, 2007, 114, 231-241.	3.9	358
26	Neuroprotection in Parkinson's disease: Myth or reality?. Current Neurology and Neuroscience Reports, 2008, 8, 304-309.	2.0	19
27	Origins and Effects of Extracellular Î±-synuclein: Implications in Parkinson's Disease. Journal of Molecular Neuroscience, 2008, 34, 17-22.	1.1	145
28	Microglial phagocytosis is enhanced by monomeric Î±-synuclein, not aggregated Î±-synuclein: Implications for Parkinson's disease. Glia, 2008, 56, 1215-1223.	2.5	123
29	A more efficient enzyme-linked immunosorbent assay for measurement of Î±-synuclein in cerebrospinal fluid. Journal of Neuroscience Methods, 2008, 168, 182-185.	1.3	32
30	Controlling the mass action of Î±-synuclein in Parkinson's disease. Journal of Neurochemistry, 2008, 107, 303-316.	2.1	90
31	Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmunity Reviews, 2008, 7, 501-507.	2.5	56
32	Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurology, The, 2008, 7, 704-714.	4.9	85
33	Chapter 6 Molecular and Cellular Biology of Synucleins. International Review of Cell and Molecular Biology, 2008, 270, 225-317.	1.6	90
34	Fitting Neurological Protein Aggregation Kinetic Data via a 2-Step, Minimal/Ockham's Razor Model: The Finke-Watzky Mechanism of Nucleation Followed by Autocatalytic Surface Growth. Biochemistry, 2008, 47, 2413-2427.	1.2	265
35	Genetic variability in the SNCA gene influences Î±-synuclein levels in the blood and brain. FASEB Journal, 2008, 22, 1327-1334.	0.2	235
36	Designing Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's Î²-Amyloid Peptide. Biochemistry, 2008, 47, 1984-1992.	1.2	142
37	Î±-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochemistry International, 2008, 53, 263-269.	1.9	53
39	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods, 2008, 44, 289-298.	1.9	38

#	ARTICLE	IF	CITATIONS
40	Assembly-dependent endocytosis and clearance of extracellular α -synuclein. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1835-1849.	1.2	428
41	Parkinson patient fibroblasts show increased alpha-synuclein expression. <i>Experimental Neurology</i> , 2008, 212, 307-313.	2.0	78
42	Direct quantification of CSF β -synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. <i>Experimental Neurology</i> , 2008, 213, 315-325.	2.0	334
43	Clearance and deposition of extracellular β -synuclein aggregates in microglia. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 423-428.	1.0	273
44	The search for biomarkers in Parkinson's disease: a critical review. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1841-1852.	1.4	31
45	β -Synuclein gene duplication is present in sporadic Parkinson disease. <i>Neurology</i> , 2008, 70, 43-49.	1.5	230
46	Early Discriminatory Diagnosis of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 195-205.	0.7	40
47	Alpha- and Gamma-Synuclein Proteins Are Present in Cerebrospinal Fluid and Are Increased in Aged Subjects with Neurodegenerative and Vascular Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 32-42.	0.7	38
48	Detection of elevated levels of soluble β -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. <i>Brain</i> , 2008, 132, 1093-1101.	3.7	203
49	GATA transcription factors directly regulate the Parkinson's disease-linked gene β -synuclein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10907-10912.	3.3	251
50	Single Particle Characterization of Iron-induced Pore-forming β -Synuclein Oligomers. <i>Journal of Biological Chemistry</i> , 2008, 283, 10992-11003.	1.6	204
51	Phosphorylation Does Not Prompt, Nor Prevent, the Formation of β -Synuclein Toxic Species in a Rat Model of Parkinson's Disease. <i>Human Molecular Genetics</i> , 2009, 18, 872-87.	1.4	172
52	Metabolomic profiling to develop blood biomarkers for Parkinson's disease. <i>Brain</i> , 2008, 131, 389-396.	3.7	362
53	Aggregopathy in Neurodegenerative Diseases: Mechanisms and Therapeutic Implication. <i>Neurodegenerative Diseases</i> , 2008, 5, 321-338.	0.8	55
54	β -Synuclein Assembly as a Therapeutic Target of Parkinson's Disease and Related Disorders. <i>Current Pharmaceutical Design</i> , 2008, 14, 3247-3266.	0.9	48
55	Dementia in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2008, 21, 676-682.	1.8	76
56	GENETICS OF PARKINSON DISEASE. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2008, 14, 90-113.	0.4	2
58	Detecting Morphologically Distinct Oligomeric Forms of β -Synuclein. <i>Journal of Biological Chemistry</i> , 2009, 284, 11048-11058.	1.6	89

#	ARTICLE	IF	CITATIONS
59	Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 2-11.	0.5	11
60	Can we image premotor Parkinson disease?. Neurology, 2009, 72, S21-6.	1.5	84
61	Expansion of the Parkinson disease-associated SNCA- Rep1 allele upregulates human α -synuclein in transgenic mouse brain. Human Molecular Genetics, 2009, 18, 3274-3285.	1.4	101
62	Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element. International Journal of Molecular Sciences, 2009, 10, 1226-1260.	1.8	75
63	Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB Journal, 2009, 23, 2384-2393.	0.2	129
64	Biomarker discovery in neurodegenerative diseases: A proteomic approach. Neurobiology of Disease, 2009, 35, 157-164.	2.1	102
65	Aging: An important factor for the pathogenesis of neurodegenerative diseases. Mechanisms of Ageing and Development, 2009, 130, 203-215.	2.2	198
66	CSF α -synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Research, 2009, 1251, 1-6.	1.1	91
67	Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment. Annals of Neurology, 2008, 64, S139-S147.	2.8	54
68	Biomarkers for Parkinson's disease: Tools to assess Parkinson's disease onset and progression. Annals of Neurology, 2008, 64, S111-S121.	2.8	35
69	Neurochemical biomarkers in the differential diagnosis of movement disorders. Movement Disorders, 2009, 24, 1411-1426.	2.2	37
70	A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. Movement Disorders, 2009, 24, 2081-2090.	2.2	48
71	PAMAM Dendrimers as Potential Agents against Fibrillation of α -Synuclein, a Parkinson's Disease-Related Protein. Macromolecular Bioscience, 2009, 9, 230-238.	2.1	62
72	Conformational Isomers of Denatured and Unfolded Proteins: Methods of Production and Applications. Protein Journal, 2009, 28, 44-56.	0.7	7
73	Immune-Directed Gene Therapeutic Development for Alzheimer's, Prion, and Parkinson's Diseases. Journal of Neuroimmune Pharmacology, 2009, 4, 298-308.	2.1	8
74	Biomarkers in Huntington's and Parkinson's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 97-110.	1.8	23
75	On the mechanism of internalization of α -synuclein into microglia: roles of ganglioside GM1 and lipid raft. Journal of Neurochemistry, 2009, 110, 400-411.	2.1	116
76	Seeding induced by α -synuclein oligomers provides evidence for spreading of α -synuclein pathology. Journal of Neurochemistry, 2009, 111, 192-203.	2.1	254

#	ARTICLE	IF	CITATIONS
77	Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases. <i>Neurotherapeutics</i> , 2009, 6, 128-140.	2.1	23
78	Anti-melanin antibodies are increased in sera in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 217, 297-301.	2.0	72
79	Identification of the amino acid sequence motif of $\hat{\alpha}$ -synuclein responsible for macrophage activation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 39-43.	1.0	50
80	Modulation effect of filamentous phage on $\hat{\alpha}$ -synuclein aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 383, 491-496.	1.0	10
81	Effects of intrahippocampal NAC61 $\hat{\alpha}$ 95 injections on memory in the rat and attenuation with vitamin E. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 945-951.	2.5	9
82	Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 90-93.	0.8	33
83	Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. <i>Neuroscience Letters</i> , 2009, 459, 16-18.	1.0	28
84	Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients. <i>Neuroscience Letters</i> , 2009, 465, 1-5.	1.0	75
85	Genomic and proteomic biomarkers for Parkinson disease. <i>Neurology</i> , 2009, 72, S27-31.	1.5	45
86	Effect of N-methyl-D-aspartate (NMDA) receptor antagonists on $\hat{\alpha}$ -synuclein-evoked neuronal nitric oxide synthase activation in the rat brain. <i>Pharmacological Reports</i> , 2009, 61, 1078-1085.	1.5	20
87	Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 157-182.	1.9	33
88	Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 130-154.	0.9	15
89	Structural Polymorphism of Amyloid Oligomers and Fibrils Underlies Different Fibrillization Pathways: Immunogenicity and Cytotoxicity. <i>Current Protein and Peptide Science</i> , 2010, 11, 343-354.	0.7	33
92	Interference from Heterophilic Antibodies in Amyloid- $\hat{\alpha}$ 2 Oligomer ELISAs. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1295-1301.	1.2	53
93	Cell-to-cell transmission of non-prion protein aggregates. <i>Nature Reviews Neurology</i> , 2010, 6, 702-706.	4.9	269
94	Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. <i>EPMA Journal</i> , 2010, 1, 273-292.	3.3	28
95	Biomarkers in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 423-430.	2.0	40
96	Screening of DNA aptamer which binds to $\hat{\alpha}$ -synuclein. <i>Biotechnology Letters</i> , 2010, 32, 643-648.	1.1	42

#	ARTICLE	IF	CITATIONS
97	Are synucleinopathies prion-like disorders?. <i>Lancet Neurology</i> , The, 2010, 9, 1128-1138.	4.9	226
98	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. <i>Neurobiology of Disease</i> , 2010, 39, 229-241.	2.1	67
99	Curcumin reduces α -synuclein induced cytotoxicity in Parkinson's disease cell model. <i>BMC Neuroscience</i> , 2010, 11, 57.	0.8	167
100	Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α -synuclein neuropathology required and feasible?. <i>Brain Research Reviews</i> , 2010, 65, 28-55.	9.1	39
101	α -Synuclein induced cell death in mouse hippocampal (HT22) cells is mediated by nitric oxide-dependent activation of caspase-3. <i>FEBS Letters</i> , 2010, 584, 3504-3508.	1.3	32
103	Sensitive and specific detection of α -synuclein in human plasma. <i>Journal of Neuroscience Research</i> , 2010, 88, 2693-2700.	1.3	25
104	Glycoproteomics in neurodegenerative diseases. <i>Mass Spectrometry Reviews</i> , 2010, 29, 79-125.	2.8	99
105	Functional correlates of lower cognitive test scores in essential tremor. <i>Movement Disorders</i> , 2010, 25, 481-485.	2.2	37
106	External validation of abbreviated versions of the activities-specific balance confidence scale in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 485-489.	2.2	34
107	Plasma α -synuclein in patients with Parkinson's disease with and without treatment. <i>Movement Disorders</i> , 2010, 25, 489-493.	2.2	93
108	Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease?. <i>Movement Disorders</i> , 2010, 25, 493-496.	2.2	37
109	Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. <i>Movement Disorders</i> , 2010, 25, 496-499.	2.2	72
110	The sour side of neurodegenerative disorders: the effects of protein glycation. <i>Journal of Pathology</i> , 2010, 221, 13-25.	2.1	138
111	Non-classical exocytosis of α -synuclein is sensitive to folding states and promoted under stress conditions. <i>Journal of Neurochemistry</i> , 2010, 113, 1263-1274.	2.1	241
112	Biomarkers: casting the net wide. <i>Nature</i> , 2010, 466, S11-S12.	13.7	26
113	Biomarkers for Cognitive Impairment in Parkinson Disease. <i>Brain Pathology</i> , 2010, 20, 660-671.	2.1	33
114	Co-expression of C-terminal truncated α -synuclein enhances full-length α -synuclein-induced pathology. <i>European Journal of Neuroscience</i> , 2010, 32, 409-422.	1.2	90
115	CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. <i>Neurology</i> , 2010, 75, 1055-1061.	1.5	315

#	ARTICLE	IF	CITATIONS
116	Î±-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010, 22, 321-327.	0.6	20
117	Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent Î±-Synuclein Oligomer Formation and Rescue Î±-Synuclein-Induced Toxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 849-857.	1.3	162
118	Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of Î±-Synuclein and Î²-Amyloid and Protect against Amyloid-induced Toxicity. <i>Journal of Biological Chemistry</i> , 2010, 285, 14941-14954.	1.6	119
119	Filamentous Phages Reduce Î±-Synuclein Oligomerization in the Membrane Fraction of SH-SY5Y Cells. <i>Neurodegenerative Diseases</i> , 2010, 7, 203-205.	0.8	9
120	Î±-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2010, 11, 4257-4266.	1.8	30
121	Î±-Synuclein Levels Are Elevated in Cerebrospinal Fluid following Traumatic Brain Injury in Infants and Children: The Effect of Therapeutic Hypothermia. <i>Developmental Neuroscience</i> , 2010, 32, 385-395.	1.0	45
122	Direct Transfer of Î±-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies. <i>Journal of Biological Chemistry</i> , 2010, 285, 9262-9272.	1.6	704
123	Progress towards a molecular biomarker for Parkinson disease. <i>Nature Reviews Neurology</i> , 2010, 6, 359-361.	4.9	18
124	Problems associated with fluid biomarkers for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010, 4, 671-681.	0.6	14
125	Cell-Produced Î±-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival. <i>Journal of Neuroscience</i> , 2010, 30, 6838-6851.	1.7	913
126	Development of Parkinson's disease biomarkers. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1811-1825.	1.4	9
127	Early Aggregation Steps in Î±-Synuclein as Measured by FCS and FRET: Evidence for a Contagious Conformational Change. <i>Biophysical Journal</i> , 2010, 98, 1302-1311.	0.2	139
128	Proteomics in Parkinson's disease: current trends, translational snags and future possibilities. <i>Expert Review of Proteomics</i> , 2010, 7, 127-139.	1.3	31
129	DJ-1 and Î±-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. <i>Brain</i> , 2010, 133, 713-726.	3.7	575
130	Detection of elevated levels of Î±-synuclein oligomers in CSF from patients with Parkinson disease. <i>Neurology</i> , 2010, 75, 1766-1770.	1.5	449
131	Quantification of Î±-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <i>Biomarkers in Medicine</i> , 2010, 4, 683-699.	0.6	113
132	Perivascular nerve fiber Î±-synuclein regulates contractility of mouse aorta: A link to autonomic dysfunction in Parkinson's disease. <i>Neurochemistry International</i> , 2010, 56, 991-998.	1.9	13
133	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 480, 78-82.	1.0	184

#	ARTICLE	IF	CITATIONS
134	Bilateral intrahippocampal NAC61â€“95 effects on behavior and moderation with l-NAME treatment. Neuroscience Research, 2010, 66, 213-218.	1.0	2
135	Behavioural deterioration induced by intrahippocampal NAC61â€“95 injections and attenuation with ibuprofen. Behavioural Brain Research, 2010, 208, 274-277.	1.2	4
136	Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2010, 16, 307-315.	1.1	31
137	Biomarkers in Parkinsonâ€™s disease: a funderâ€™s perspective. Biomarkers in Medicine, 2010, 4, 723-729.	0.6	13
138	Heatâ€™shock protein 70 modulates toxic extracellular Î±-synuclein oligomers and rescues transâ€™synaptic toxicity. FASEB Journal, 2011, 25, 326-336.	0.2	276
139	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. Molecular Diagnosis and Therapy, 2011, 15, 83-102.	1.6	25
140	A Universal Method for Detection of Amyloidogenic Misfolded Proteins. Biochemistry, 2011, 50, 4322-4329.	1.2	34
141	Parkinsonâ€™s disease-associated mutations in Î±-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1. Neurochemistry International, 2011, 59, 251-258.	1.9	8
142	Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. Neuroscience Research, 2011, 70, 339-348.	1.0	154
143	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in Neurobiology, 2011, 95, 601-613.	2.8	32
144	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	2.8	1,278
145	Dynamic modeling of Î±-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy. Neuroscience, 2011, 199, 303-317.	1.1	18
146	Elevated Levels of Î±-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with		

#	ARTICLE	IF	CITATIONS
154	Diagnostic markers for Parkinson's disease. <i>Current Opinion in Neurology</i> , 2011, 24, 309-317.	1.8	38
155	Parkinson's disease: diagnostic relevance of elevated levels of soluble α -synuclein oligomers in cerebrospinal fluid. <i>Future Neurology</i> , 2011, 6, 159-163.	0.9	4
156	AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α -synuclein oligomers. <i>Journal of Neurochemistry</i> , 2011, 117, 868-878.	2.1	60
157	α -Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death. <i>Journal of Neurochemistry</i> , 2011, 119, 815-825.	2.1	68
158	Priorities in Parkinson's disease research. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 377-393.	21.5	364
159	A deadly spread: cellular mechanisms of α -synuclein transfer. <i>Cell Death and Differentiation</i> , 2011, 18, 1425-1433.	5.0	131
160	Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. <i>Journal of Neuroimmunology</i> , 2011, 233, 221-227.	1.1	95
161	α -Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. <i>Journal of Clinical Investigation</i> , 2011, 121, 715-725.	3.9	722
162	CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. <i>Integrative Biology (United Kingdom)</i> , 2011, 3, 1188-1196.	0.6	72
163	Parkinson's disease and α -synuclein expression. <i>Movement Disorders</i> , 2011, 26, 2160-2168.	2.2	186
164	Baicalein Inhibits Formation of α -Synuclein Oligomers within Living Cells and Prevents $A\beta$ Peptide Fibrillation and Oligomerisation. <i>ChemBioChem</i> , 2011, 12, 615-624.	1.3	140
165	Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities. <i>Journal of Neuroscience Methods</i> , 2011, 199, 249-257.	1.3	24
167	Detection of elevated levels of α -synuclein oligomers in CSF from patients with Parkinson disease. <i>Neurology</i> , 2011, 77, 510-511.	1.5	16
168	α -Synuclein in Parkinson disease and other neurodegenerative disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 403-408.	1.4	63
169	Parkinson's disease – the continuing search for biomarkers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 393-401.	1.4	18
170	Phosphorylated α -synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. <i>FASEB Journal</i> , 2011, 25, 4127-4137.	0.2	186
171	Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?. <i>Frontiers in Physiology</i> , 2012, 3, 124.	1.3	339
172	An extracellular mechanism that can explain the neurotoxic effects of α -synuclein aggregates in the brain. <i>Frontiers in Physiology</i> , 2012, 3, 297.	1.3	38

#	ARTICLE	IF	CITATIONS
173	Correlation between Protective Immunity to $\hat{\pm}$ -Synuclein Aggregates, Oxidative Stress and Inflammation. <i>NeuroImmunoModulation</i> , 2012, 19, 334-342.	0.9	35
174	Antibody-Aided Clearance of Extracellular $\hat{\pm}$ -Synuclein Prevents Cell-to-Cell Aggregate Transmission. <i>Journal of Neuroscience</i> , 2012, 32, 13454-13469.	1.7	290
175	New concepts in the early and preclinical detection of Parkinsonâ€™s disease: therapeutic implications. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1429-1438.	1.4	18
176	Native Chemical Ligation of Thioamide-Containing Peptides: Development and Application to the Synthesis of Labeled $\hat{\pm}$ -Synuclein for Misfolding Studies. <i>Journal of the American Chemical Society</i> , 2012, 134, 9172-9182.	6.6	86
177	Novel One-step Immunoassays to Quantify $\hat{\pm}$ -Synuclein. <i>Journal of Biological Chemistry</i> , 2012, 287, 33691-33705.	1.6	51
178	Does a prion-like mechanism play a major role in the apparent spread of $\hat{\pm}$ -synuclein pathology?. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 48.	3.0	5
179	Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 245-259.	2.5	18
180	Selection of DNA Aptamers That Recognize $\hat{\pm}$ -Synuclein Oligomers Using a Competitive Screening Method. <i>Analytical Chemistry</i> , 2012, 84, 5542-5547.	3.2	167
181	$\hat{\beta}$ -Synuclein: Seeding of $\hat{\pm}$ -Synuclein Aggregation and Transmission between Cells. <i>Biochemistry</i> , 2012, 51, 4743-4754.	1.2	79
182	Effect of melatonin on $\hat{\pm}$ -synuclein self-assembly and cytotoxicity. <i>Neurobiology of Aging</i> , 2012, 33, 2172-2185.	1.5	77
183	Proteolytic Cleavage of Extracellular $\hat{\pm}$ -Synuclein by Plasmin. <i>Journal of Biological Chemistry</i> , 2012, 287, 24862-24872.	1.6	67
184	Beyond $\hat{\pm}$ -synuclein transfer: pathology propagation in Parkinson's disease. <i>Trends in Molecular Medicine</i> , 2012, 18, 248-255.	3.5	69
185	Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for $A\hat{\beta}$ oligomers. <i>Biochemical and Biophysical Research Communications</i> , 2012, 422, 375-380.	1.0	10
186	Premotor biomarkers for Parkinson's disease - a promising direction of research. <i>Translational Neurodegeneration</i> , 2012, 1, 11.	3.6	54
187	Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity. <i>International Immunopharmacology</i> , 2012, 14, 550-557.	1.7	12
188	Phosphorylated $\hat{\pm}$ -synuclein as a potential biomarker for Parkinsonâ€™s disease and related disorders. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 115-117.	1.5	15
189	Dysfunction of two lysosome degradation pathways of $\hat{\pm}$ -synuclein in Parkinsonâ€™s disease: potential therapeutic targets?. <i>Neuroscience Bulletin</i> , 2012, 28, 649-657.	1.5	12
190	Exosomal cell-to-cell transmission of alpha synuclein oligomers. <i>Molecular Neurodegeneration</i> , 2012, 7, 42.	4.4	708

#	ARTICLE	IF	CITATIONS
191	Suppression of dynamin GTPase decreases α -synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. <i>Molecular Neurodegeneration</i> , 2012, 7, 38.	4.4	107
192	α -Synuclein and Anti- α -Synuclein Antibodies in Parkinson's Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls. <i>PLoS ONE</i> , 2012, 7, e52285.	1.1	59
193	α -Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers. <i>PLoS ONE</i> , 2012, 7, e52312.	1.1	45
194	α -Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-9.	1.1	34
195	α -Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer. <i>Journal of Biological Chemistry</i> , 2012, 287, 15345-15364.	1.6	466
196	α -Synuclein aggregation in the saliva of familial transthyretin amyloidosis: a potential biomarker. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 74-80.	1.4	10
197	Premotor Parkinson's disease: Concepts and definitions. <i>Movement Disorders</i> , 2012, 27, 608-616.	2.2	140
198	Biochemical premotor biomarkers for Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 644-650.	2.2	37
199	An antibody with high reactivity for disease-associated α -synuclein reveals extensive brain pathology. <i>Acta Neuropathologica</i> , 2012, 124, 37-50.	3.9	133
200	Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. <i>Brain</i> , 2012, 135, 1900-1913.	3.7	115
201	α -Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. <i>Journal of Neurochemistry</i> , 2012, 120, 440-452.	2.1	94
202	TR-FRET-Based Duplex Immunoassay Reveals an Inverse Correlation of Soluble and Aggregated Mutant huntingtin in Huntington's Disease. <i>Chemistry and Biology</i> , 2012, 19, 264-275.	6.2	70
203	Pathogenic and physiological autoantibodies in the central nervous system. <i>Immunological Reviews</i> , 2012, 248, 68-86.	2.8	36
204	Post mortem cerebrospinal fluid α -synuclein levels are raised in multiple system atrophy and distinguish this from the other α -synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2012, 45, 188-195.	2.1	84
205	The role of α -synuclein in neurodegeneration – An update. <i>Translational Neuroscience</i> , 2012, 3, .	0.7	16
206	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <i>Journal of Neural Transmission</i> , 2012, 119, 39-52.	1.4	68
207	Variant in the 3' region of SNCA associated with Parkinson's disease and serum α -synuclein levels. <i>Journal of Neurology</i> , 2012, 259, 497-504.	1.8	37
208	Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies. <i>Neurotherapeutics</i> , 2013, 10, 371-382.	2.1	33

#	ARTICLE	IF	CITATIONS
209	Microglial Activation and Antioxidant Responses Induced by the Parkinson's Disease Protein α -Synuclein. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 94-117.	2.1	145
210	Sensitive detection of protein and miRNA cancer biomarkers using silicon-based photonic crystals and a resonance coupling laser scanning platform. <i>Lab on A Chip</i> , 2013, 13, 4053.	3.1	58
211	Exploring the accessible conformations of N-terminal acetylated α -synuclein. <i>FEBS Letters</i> , 2013, 587, 1128-1138.	1.3	29
212	Neonatal exposure to lipopolysaccharide enhances accumulation of α -synuclein aggregation and dopamine transporter protein expression in the substantia nigra in responses to rotenone challenge in later life. <i>Toxicology</i> , 2013, 308, 96-103.	2.0	16
213	A longitudinal study on α -synuclein in blood plasma as a biomarker for Parkinson's disease. <i>Scientific Reports</i> , 2013, 3, 2540.	1.6	142
214	Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 3543-3558.	2.5	159
215	Neurodegenerative Diseases: Integrative PPM Approach as the Medicine of the Future. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2013, , .	0.6	3
216	The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. <i>Biochemical Journal</i> , 2013, 452, 1-17.	1.7	126
218	Biomarkers, Mechanisms, and Potential Prevention of Catecholamine Neuron Loss in Parkinson Disease. <i>Advances in Pharmacology</i> , 2013, 68, 235-272.	1.2	28
219	Oxidative and nitrative α -synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. <i>Journal of Neurochemistry</i> , 2013, 125, 491-511.	2.1	116
220	Can Intrabodies Serve as Neuroprotective Therapies for Parkinson's Disease? Beginning Thoughts. <i>Journal of Parkinson's Disease</i> , 2013, 3, 581-591.	1.5	18
221	Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?. <i>Journal of Neural Transmission</i> , 2013, 120, 197-210.	1.4	17
222	α -Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.	2.8	255
223	Biomarkers of Parkinson's disease: current status and future perspectives. <i>Drug Discovery Today</i> , 2013, 18, 155-162.	3.2	52
224	GC-MS analysis of Eucalyptus citriodora leaf extract and its role on the dietary supplementation in transgenic Drosophila model of Parkinson's disease. <i>Food and Chemical Toxicology</i> , 2013, 55, 29-35.	1.8	38
225	Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. <i>Molecular and Cellular Neurosciences</i> , 2013, 54, 71-83.	1.0	143
226	Gender differences in Parkinson's disease: focus on plasma alpha-synuclein. <i>Journal of Neural Transmission</i> , 2013, 120, 1209-1215.	1.4	42
227	Toxicity of extracellular secreted alpha-synuclein: Its role in nitrosative stress and neurodegeneration. <i>Neurochemistry International</i> , 2013, 62, 776-783.	1.9	29

#	ARTICLE	IF	CITATIONS
228	The secreted oligomeric form of α -synuclein affects multiple steps of membrane trafficking. FEBS Letters, 2013, 587, 452-459.	1.3	25
229	Biomarkers for trials of neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 71-85.	2.2	22
232	Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. Journal of Parkinson's Disease, 2013, 3, 415-459.	1.5	68
233	Synthesis of Alginate-Curcumin Nanocomposite and Its Protective Role in Transgenic <i>Drosophila</i> Model of Parkinson's Disease. ISRN Pharmacology, 2013, 2013, 1-8.	1.6	54
235	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
237	Ebolavirus Nucleoprotein C-Termini Potently Attract Single Domain Antibodies Enabling Monoclonal Affinity Reagent Sandwich Assay (MARSA) Formulation. PLoS ONE, 2013, 8, e61232.	1.1	29
238	Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders. Frontiers in Neurology, 2012, 3, 187.	1.1	28
239	Alpha-Synuclein Function and Dysfunction on Cellular Membranes. Experimental Neurobiology, 2014, 23, 292-313.	0.7	179
240	Extracellular α -Synuclein Leads to Microtubule Destabilization via GSK-3 β -Dependent Tau Phosphorylation in PC12 Cells. PLoS ONE, 2014, 9, e94259.	1.1	62
241	Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson's Disease: Sources of (Error) Variance in Biomarker Assays. PLoS ONE, 2014, 9, e114566.	1.1	24
242	Copper and Copper Proteins in Parkinson's Disease. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-15.	1.9	136
243	Protein Aggregation: Elucidation of the Mechanism and Determination of Associated Thermodynamic and Kinetic Parameters. Current Physical Chemistry, 2014, 4, 114-136.	0.1	15
244	Oxidized DJ-1 as a possible biomarker of Parkinson's disease. Journal of Clinical Biochemistry and Nutrition, 2014, 54, 138-144.	0.6	58
245	Detection of disease-associated α -synuclein in the cerebrospinal fluid: a feasibility study. , 2014, 33, 329-334.		19
246	Immunotherapy targeting α -synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Immunotherapy, 2014, 6, 141-153.	1.0	48
247	Autophagy modulates SNCA/ α -synuclein release, thereby generating a hostile microenvironment. Autophagy, 2014, 10, 2171-2192.	4.3	174
248	Prion-like activity of Cu/Zn superoxide dismutase. Prion, 2014, 8, 33-41.	0.9	57
249	Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimer's Research and Therapy, 2014, 6, 72.	3.0	28

#	ARTICLE	IF	CITATIONS
250	Increase of the plasma α -synuclein levels in patients with multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 375-379.	2.2	20
251	Biomarkers of Parkinson's disease. , 2014, , 817-831.		0
252	Elevated levels of cerebrospinal fluid α -synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 248.	1.7	59
253	Structure activity relationship of phenolic acid inhibitors of α -synuclein fibril formation and toxicity. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 197.	1.7	103
254	Blood and cerebrospinal fluid markers in Parkinson's disease: current biomarker findings. <i>Current Biomarker Findings</i> , 0, , 1.	0.4	7
255	α -Synuclein in Parkinson's Disease: Pathogenic Function and Translation into Animal Models. <i>Neurodegenerative Diseases</i> , 2014, 14, 1-17.	0.8	39
257	PAR2-mediated epigenetic upregulation of α -synuclein contributes to the pathogenesis of Parkinson's disease. <i>Brain Research</i> , 2014, 1565, 82-89.	1.1	21
258	Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 59-72.	1.0	141
259	Blood-based biomarkers for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S99-S103.	1.1	117
260	Lewy body extracts from Parkinson disease brains trigger α -synuclein pathology and neurodegeneration in mice and monkeys. <i>Annals of Neurology</i> , 2014, 75, 351-362.	2.8	521
261	Epigenetic upregulation of alpha-synuclein in the rats exposed to methamphetamine. <i>European Journal of Pharmacology</i> , 2014, 745, 243-248.	1.7	35
262	Alpha synuclein is transported into and out of the brain by the blood-brain barrier. <i>Peptides</i> , 2014, 62, 197-202.	1.2	138
263	Plasma exosomal α -synuclein is likely CNS-derived and increased in Parkinson's disease. <i>Acta Neuropathologica</i> , 2014, 128, 639-650.	3.9	504
264	Structural Characterization of Heparin-induced Glyceraldehyde-3-phosphate Dehydrogenase Protofibrils Preventing α -Synuclein Oligomeric Species Toxicity. <i>Journal of Biological Chemistry</i> , 2014, 289, 13838-13850.	1.6	31
265	What can biomarkers tell us about cognition in Parkinson's disease?. <i>Movement Disorders</i> , 2014, 29, 622-633.	2.2	61
266	Levels of cerebrospinal fluid α -synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 25.	3.0	169
267	Fc γ RIIB mediates the inhibitory effect of aggregated α -synuclein on microglial phagocytosis. <i>Neurobiology of Disease</i> , 2015, 83, 90-99.	2.1	64
268	Transient α -hairpin formation in α -synuclein monomer revealed by coarse-grained molecular dynamics simulation. <i>Journal of Chemical Physics</i> , 2015, 143, 243142.	1.2	73

#	ARTICLE	IF	CITATIONS
269	Detection of Disease-associated α -synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α -synuclein. <i>Journal of Visualized Experiments</i> , 2015, , e52752.	0.2	3
270	The associations between Parkinson's disease and cancer: the plot thickens. <i>Translational Neurodegeneration</i> , 2015, 4, 20.	3.6	77
271	Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. <i>Journal of Parkinson's Disease</i> , 2015, 5, 413-424.	1.5	69
272	Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell Models. <i>Biomolecules</i> , 2015, 5, 1634-1651.	1.8	33
273	The Potential of Pathological Protein Fragmentation in Blood-Based Biomarker Development for Dementia – With Emphasis on Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 90.	1.1	16
274	Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. <i>Frontiers in Neuroscience</i> , 2015, 9, 59.	1.4	97
275	Distinct higher-order α -synuclein oligomers induce intracellular aggregation. <i>Biochemical Journal</i> , 2015, 468, 485-493.	1.7	34
276	The association between infectious burden and Parkinson's disease: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 877-881.	1.1	116
277	The N-Terminus of α -Synuclein Forms Cu-Bridged Oligomers. <i>Chemistry - A European Journal</i> , 2015, 21, 7111-7118.	1.7	21
278	Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. <i>Brain</i> , 2015, 138, 1642-1657.	3.7	211
279	Detection of α -synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. <i>Neuroscience Letters</i> , 2015, 599, 115-119.	1.0	121
280	Extracellular α -synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. <i>Journal of Neurochemistry</i> , 2015, 132, 731-741.	2.1	71
281	Au Nanostructured Surfaces for Electrochemical and Localized Surface Plasmon Resonance-Based Monitoring of α -Synuclein-Small Molecule Interactions. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 4081-4088.	4.0	29
282	Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. <i>Biological Psychiatry</i> , 2015, 78, 672-683.	0.7	140
283	Extracellular vesicles – Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. <i>Seminars in Cell and Developmental Biology</i> , 2015, 40, 89-96.	2.3	178
284	From molecule to molecule and cell to cell: Prion-like mechanisms in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2015, 77, 257-265.	2.1	74
285	Targeting α -synuclein as a therapeutic strategy for Parkinson's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1351-1360.	1.5	19
286	Increased oligomerization and phosphorylation of α -synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains. <i>Neurobiology of Aging</i> , 2015, 36, 2649-2659.	1.5	54

#	ARTICLE	IF	CITATIONS
287	RNA Structures as Mediators of Neurological Diseases and as Drug Targets. <i>Neuron</i> , 2015, 87, 28-46.	3.8	105
288	Generation and characterization of novel conformation-specific monoclonal antibodies for α -synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	2.1	116
289	Biomarker sources for Parkinson's disease: Time to shed tears?. <i>Basal Ganglia</i> , 2015, 5, 63-69.	0.3	21
290	Development of a Highly Potent D ₂ /D ₃ Agonist and a Partial Agonist from Structure-Activity Relationship Study of N -(2-(4-(1 <i>H</i> -Indol-5-yl)piperazin-1-yl)ethyl)- N -propyl-4,5,6,7-tetrahydrobenzo[<i>d</i>]imidazole Analogues: Implication in the Treatment of Parkinson's Disease. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8178-8185.	1.0	1
291	Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α -synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. <i>Neuroscience</i> , 2015, 286, 383-392.	1.1	81
292	Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1 α deregulation and α -synuclein oligomerization. <i>Annals of Neurology</i> , 2015, 77, 15-32.	2.8	112
293	Zinc-induced structural changes of the disordered tppp/p25 inhibits its degradation by the proteasome. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 83-91.	1.8	9
294	The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease. <i>Neuroscience</i> , 2015, 302, 74-88.	1.1	110
295	A Sensitive phage-based capture ϕ -ELISA for sub-femtomolar detection of protein variants directly from biological samples. <i>Biotechnology Progress</i> , 2015, 31, 289-298.	1.3	13
297	Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease. , 0, , 249-264.		0
298	Proteomics and Human Diseases. <i>Journal of Proteomics and Bioinformatics</i> , 2016, 09, .	0.4	9
299	Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity. <i>Parkinson's Disease</i> , 2016, 2016, 1-14.	0.6	11
300	Parkinson's Disease: Assay of Phosphorylated α -Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma. <i>Brain Sciences</i> , 2016, 6, 17.	1.1	8
301	A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo. <i>Frontiers in Neuroscience</i> , 2015, 9, 511.	1.4	5
302	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. <i>Movement Disorders</i> , 2016, 31, 771-781.	2.2	88
303	Current status of biomarker research in neurology. <i>EPMA Journal</i> , 2016, 7, 14.	3.3	36
304	Structural and functional properties of prefibrillar α -synuclein oligomers. <i>Scientific Reports</i> , 2016, 6, 24526.	1.6	125
305	Salivary total α -synuclein, oligomeric α -synuclein and SNCA variants in Parkinson's disease patients. <i>Scientific Reports</i> , 2016, 6, 28143.	1.6	55

#	ARTICLE	IF	CITATIONS
306	Biomarkers in Prodromal Parkinson Disease: a Qualitative Review. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 956-967.	1.2	19
307	Alpha-Synuclein as a Diagnostic Biomarker for Parkinson's Disease. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 215-234.	0.1	1
309	Effects of pramipexole treatment on the α -synuclein content in serum exosomes of Parkinson's disease patients. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1373-1376.	0.8	9
310	α -Synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 588-606.	1.7	36
311	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016, 11, 61.	4.4	39
312	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. <i>Movement Disorders</i> , 2016, 31, 848-860.	2.2	52
313	Oligomeric α -synuclein and β -amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. <i>European Journal of Neuroscience</i> , 2016, 43, 3-16.	1.2	59
314	Can pathological oligomeric proteins make good biomarkers? (Commentary on Williams <i>et al</i> .). <i>European Journal of Neuroscience</i> , 2016, 43, 1-2.	1.2	0
315	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 77-94.	1.8	163
316	Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 51-76.	1.8	65
318	Emerging understanding of the protein corona at the nano-bio interfaces. <i>Nano Today</i> , 2016, 11, 817-832.	6.2	205
319	Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. <i>Acta Neuropathologica Communications</i> , 2016, 4, 87.	2.4	40
320	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 7.	4.4	198
321	Alpha-Synuclein as a Biomarker for Parkinson's Disease. <i>Brain Pathology</i> , 2016, 26, 410-418.	2.1	217
322	Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids. <i>ACS Chemical Neuroscience</i> , 2016, 7, 399-406.	1.7	99
323	Mesenchymal Stem Cells Inhibit Transmission of α -Synuclein by Modulating Clathrin-Mediated Endocytosis in a Parkinsonian Model. <i>Cell Reports</i> , 2016, 14, 835-849.	2.9	66
324	Induction of α -synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 481-494.	3.7	349
325	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	2.1	58

#	ARTICLE	IF	CITATIONS
326	É-Synuclein strains and the variable pathologies of synucleinopathies. Journal of Neurochemistry, 2016, 139, 256-274.	2.1	72
327	CSF biomarkers in neurodegenerative and vascular dementias. Progress in Neurobiology, 2016, 138-140, 36-53.	2.8	34
328	Decreased Toll-Like Receptor 2 and Toll-Like Receptor 7/8-Induced Cytokines in Parkinson's Disease Patients. NeuroImmunoModulation, 2016, 23, 58-66.	0.9	28
329	Effects of different isoforms of apoE on aggregation of the Î±-synuclein protein implicated in Parkinson's disease. Neuroscience Letters, 2016, 618, 146-151.	1.0	28
330	The utility of Î±-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomarkers in Medicine, 2016, 10, 19-34.	0.6	86
331	Protective effects of activated signaling pathways by insulin on C6 glial cell model of MPP ⁺ -induced Parkinson's disease. Journal of Receptor and Signal Transduction Research, 2017, 37, 100-107.	1.3	12
332	Personalized protein corona on nanoparticles and its clinical implications. Biomaterials Science, 2017, 5, 378-387.	2.6	227
333	Aptasensors for the selective detection of alpha-synuclein oligomer by colorimetry, surface plasmon resonance and electrochemical impedance spectroscopy. Sensors and Actuators B: Chemical, 2017, 245, 87-94.	4.0	70
334	Retinal biomarkers provide insight into cortical pharmacology and disease. , 2017, 175, 151-177.		34
336	Nanoparticle standards for immuno-based quantitation of Î±-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies. Clinica Chimica Acta, 2017, 466, 152-159.	0.5	21
337	Alpha-Synuclein in Cerebrospinal Fluid. , 2017, , 171-192.		0
338	Spine Topographical Distribution of Skin Î±-Synuclein Deposits in Idiopathic Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2017, 76, 384-389.	0.9	36
339	The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. Biomarkers in Medicine, 2017, 11, 359-368.	0.6	50
340	Lewy body dementia. , 2017, , 175-198.		2
341	Novel evidence associates higher plasma Î±-synuclein levels and cognitive impairment in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 808-808.	0.9	7
342	Development of a Biochemical Diagnosis of Parkinson Disease by Detection of Î±-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurology, 2017, 74, 163.	4.5	312
343	The Oligomer Hypothesis in Î±-Synucleinopathy. Neurochemical Research, 2017, 42, 3362-3371.	1.6	53
344	Î±-Synuclein Interacts with Lipoproteins in Plasma. Journal of Molecular Neuroscience, 2017, 63, 165-172.	1.1	32

#	ARTICLE	IF	CITATIONS
345	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
346	Alpha-synuclein oligomers: a new hope. <i>Acta Neuropathologica</i> , 2017, 134, 819-838.	3.9	260
347	A Preliminary Study on Investigation of Serum α -Synuclein and Tau Protein Levels in Children with Attention Deficit Hyperactivity Disorder. <i>Indian Journal of Clinical Biochemistry</i> , 2017, 32, 285-291.	0.9	6
348	DJ-1 as a Biomarker of Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1037, 149-171.	0.8	29
349	Biomarkers in Neurodegenerative Diseases. <i>Advances in Neurobiology</i> , 2017, 15, 491-528.	1.3	69
350	The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α -Synuclein Aggregates in Parkinsonian Models. <i>Stem Cells Translational Medicine</i> , 2017, 6, 949-961.	1.6	47
351	Antibodies against the C-terminus of α -synuclein modulate its fibrillation. <i>Biophysical Chemistry</i> , 2017, 220, 34-41.	1.5	29
353	Potential Modes of Intercellular α -Synuclein Transmission. <i>International Journal of Molecular Sciences</i> , 2017, 18, 469.	1.8	76
354	Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach. <i>Frontiers in Neuroscience</i> , 2017, 11, 3.	1.4	44
355	Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein. <i>Frontiers in Neuroscience</i> , 2017, 11, 172.	1.4	91
356	Commentary: α -Synuclein Interacts with Lipoproteins in Plasma. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 362.	1.4	4
357	The Contribution of α -Synuclein Spreading to Parkinson's Disease Synaptopathy. <i>Neural Plasticity</i> , 2017, 2017, 1-15.	1.0	70
358	Investigation of the effects of carbon-based nanomaterials on A53T alpha-synuclein aggregation using a whole-cell recombinant biosensor. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 8831-8840.	3.3	39
359	Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes. <i>Journal of Neuroinflammation</i> , 2017, 14, 241.	3.1	35
360	Modification of α -Synuclein by Phosphorylation: A Pivotal Event in the Cellular Pathogenesis of Parkinson's Disease. , 2017, , .		1
361	Structure, Distribution, and Genetic Profile of α -Synuclein and Their Potential Clinical Application in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2017, 10, 69-79.	0.7	20
362	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018, 33, 528-536.	2.2	17
363	Release and uptake of pathologic alpha-synuclein. <i>Cell and Tissue Research</i> , 2018, 373, 175-182.	1.5	57

#	ARTICLE	IF	CITATIONS
364	The relation between plasma α -synuclein level and clinical symptoms or signs of Parkinson's disease. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 243-251.	0.6	33
365	Plasma α -synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. <i>Neurobiology of Disease</i> , 2018, 116, 53-59.	2.1	29
366	Extracellular α -Synuclein Disrupts Membrane Nanostructure and Promotes S-Nitrosylation-Induced Neuronal Cell Death. <i>Biomacromolecules</i> , 2018, 19, 1118-1129.	2.6	14
367	Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. <i>Molecular Neurobiology</i> , 2018, 55, 8728-8737.	1.9	38
368	AMBRA1, a novel α -synuclein-binding protein, is implicated in the pathogenesis of multiple system atrophy. <i>Brain Pathology</i> , 2018, 28, 28-42.	2.1	25
369	α -Synuclein Aggregates with β -Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects. <i>Molecular Neurobiology</i> , 2018, 55, 2653-2675.	1.9	32
370	Cell Biology and Pathophysiology of α -Synuclein. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a024091.	2.9	353
371	Levels of α - and β -synuclein regulate cellular susceptibility to toxicity from α -synuclein oligomers. <i>FASEB Journal</i> , 2018, 32, 995-1006.	0.2	9
372	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
373	Interaction of Alpha-synuclein with Cytogaligin, a protein encoded by the proapoptotic gene GALIG. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 787-792.	1.0	4
374	Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. <i>Neuroscience Letters</i> , 2018, 672, 145-149.	1.0	35
375	Cervical skin denervation associates with α -synuclein aggregates in Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1394-1407.	1.7	39
376	The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 946.	1.1	42
377	Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4129.	1.8	24
378	Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 413.	1.8	9
379	Recent Advances in Biomarkers for Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 305.	1.7	120
380	Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. <i>Frontiers in Neuroscience</i> , 2018, 12, 612.	1.4	340
381	Separation and determination of α -synuclein monomeric and oligomeric species using two electrophoretic approaches. <i>Electrophoresis</i> , 2018, 39, 3022-3031.	1.3	11

#	ARTICLE	IF	CITATIONS
382	Candidate biomarkers for Parkinson's disease. <i>Biomedicine and Pharmacotherapy</i> , 2018, 104, 699-704.	2.5	20
383	Drug-Abuse Nanotechnology: Opportunities and Challenges. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2288-2298.	1.7	7
384	Epigenetic Modifications of the α -Synuclein Gene and Relative Protein Content Are Affected by Ageing and Physical Exercise in Blood from Healthy Subjects. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-16.	1.9	16
385	ELISA method to detect α -synuclein oligomers in cell and animal models. <i>PLoS ONE</i> , 2018, 13, e0196056.	1.1	54
386	α -Synuclein Heterocomplexes with β -Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 53.	1.4	51
387	Non-cell-autonomous actions of α -synuclein: Implications in glial synucleinopathies. <i>Progress in Neurobiology</i> , 2018, 169, 158-171.	2.8	21
388	Real-time determination of aggregated alpha-synuclein induced membrane disruption at neuroblastoma cells using scanning ion conductance microscopy. <i>Faraday Discussions</i> , 2018, 210, 131-143.	1.6	8
389	Diagnostic biomarkers for Parkinson's disease at a glance: where are we?. <i>Journal of Neural Transmission</i> , 2018, 125, 1417-1432.	1.4	65
390	Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases. <i>Molecular Neurobiology</i> , 2019, 56, 2256-2277.	1.9	43
391	Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review. <i>Journal of Neural Transmission</i> , 2019, 126, 1373-1382.	1.4	34
392	Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1149-1161.	1.4	2
393	Erythrocytes as Biomarkers for Dementia: Analysis of Protein Content and Alpha-Synuclein. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 569-580.	1.2	12
394	High Levels of β -Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-16.	1.9	18
395	Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3148.	1.8	37
396	Parkinson's disease biomarkers based on α -synuclein. <i>Journal of Neurochemistry</i> , 2019, 150, 626-636.	2.1	104
397	Immunoassay of plasmonic gold nanoparticle clusters: Plasmon coupling effects for Parkinson biomarker detection. <i>Journal of the Chinese Chemical Society</i> , 2019, 66, 982-987.	0.8	15
398	Intracellular and Intercellular Mitochondrial Dynamics in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 930.	1.4	55
399	Stabilization of α -synuclein oligomers using formaldehyde. <i>PLoS ONE</i> , 2019, 14, e0216764.	1.1	20

#	ARTICLE	IF	CITATIONS
400	Prion-like propagation of β -synuclein in neurodegenerative diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 323-348.	0.9	18
401	Interactions between two regulatory proteins of microtubule dynamics, HDAC6, TPPP/p25, and the hub protein, DYNLL/LC8. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118556.	1.9	4
402	Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. <i>Scientific Reports</i> , 2019, 9, 544.	1.6	94
403	Decoding epigenetic cell signaling in neuronal differentiation. <i>Seminars in Cell and Developmental Biology</i> , 2019, 95, 12-24.	2.3	10
404	Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. <i>Neurological Sciences</i> , 2019, 40, 929-938.	0.9	59
405	Erythrocytic β -Synuclein as a potential biomarker for Parkinson's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 15.	3.6	65
406	Skin Fibroblasts as the Object for Clinical Diagnosis of Parkinson's Disease in Persons of Different Ages. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 167, 177-181.	0.3	5
407	Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease. <i>BMC Neurology</i> , 2019, 19, 113.	0.8	11
408	Enhancing the Astrocytic Clearance of Extracellular β -Synuclein Aggregates by Ginkgolides Attenuates Neural Cell Injury. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 1017-1028.	1.7	24
409	The early diagnosis of Parkinson's disease through combined biomarkers. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 268-273.	1.0	9
410	Antibodies against alpha-synuclein: tools and therapies. <i>Journal of Neurochemistry</i> , 2019, 150, 612-625.	2.1	53
411	Dissecting the Interactions between Human Serum Albumin and β -Synuclein: New Insights on the Factors Influencing β -Synuclein Aggregation in Biological Fluids. <i>Journal of Physical Chemistry B</i> , 2019, 123, 4380-4386.	1.2	25
412	Potential Diagnostic Value of Red Blood Cells β -Synuclein Heteroaggregates in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 6451-6459.	1.9	24
413	Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of β -Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2741-2755.	1.7	18
414	Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00470.	1.1	71
415	Biomarkers of Parkinson's Disease. , 2019, , 895-909.		0
416	Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. <i>Acta Neuropathologica</i> , 2019, 137, 455-466.	3.9	45
417	Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 143-148.	1.1	61

#	ARTICLE	IF	CITATIONS
418	A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α -Synuclein in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2019, 19, 204-210.	0.8	13
419	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	0.9	74
420	Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice. <i>Journal of Neuroinflammation</i> , 2019, 16, 250.	3.1	85
421	α -Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 696, 114-120.	1.0	113
422	Cerebrospinal fluid biomarker for Parkinson's disease: An overview. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 60-66.	1.0	32
423	Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 124, 163-175.	2.1	33
424	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 397-416.	2.1	34
425	Increased Serum Levels of α -Synuclein in Patients With Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 280-286.	0.6	18
426	Heterogeneity in α -synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 597-608.	1.8	27
427	The usual suspects, dopamine and α -synuclein, conspire to cause neurodegeneration. <i>Movement Disorders</i> , 2019, 34, 167-179.	2.2	62
428	Extracellular vesicles, new actors in the search for biomarkers of dementias. <i>Neurobiology of Aging</i> , 2019, 74, 15-20.	1.5	32
429	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 417-434.	2.1	15
430	Alpha-synuclein in erythrocyte membrane of patients with multiple system atrophy: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 105-110.	1.1	11
431	GBA1 mutations: Prospects for exosomal biomarkers in α -synuclein pathologies. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 35-46.	0.5	11
432	Open questions on the nature of Parkinson's disease: from triggers to spreading pathology. <i>Journal of Medical Genetics</i> , 2020, 57, 73-81.	1.5	17
433	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 180-184.	2.2	66
434	Gold-nanourchin seeded single-walled carbon nanotube on voltammetry sensor for diagnosing neurodegenerative Parkinson's disease. <i>Analytica Chimica Acta</i> , 2020, 1094, 142-150.	2.6	46
435	An aptamer based fluorometric assay for amyloid- β oligomers using a metal-organic framework of type ARu@MIL-101(Al) and enzyme-assisted recycling. <i>Mikrochimica Acta</i> , 2020, 187, 114.	2.5	15

#	ARTICLE	IF	CITATIONS
436	NK cells clear α -synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α -synucleinopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1762-1771.	3.3	77
437	Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 309.	4.5	108
438	Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model. <i>Molecular and Cellular Biochemistry</i> , 2020, 465, 89-102.	1.4	36
439	Alpha-synuclein oligomerization and dopaminergic degeneration occur synchronously in the brain and colon of MPTP-intoxicated parkinsonian monkeys. <i>Neuroscience Letters</i> , 2020, 716, 134640.	1.0	15
440	α -Synuclein Real-Time Quaking-Induced Conversion in the Submandibular Glands of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020, 35, 268-278.	2.2	98
441	New markers in Parkinson's disease. <i>Advances in Clinical Chemistry</i> , 2020, 96, 137-178.	1.8	16
442	Differential Diagnosis of Multiple System Atrophy-Parkinsonism and Parkinson's Disease Using α -Synuclein and External Anal Sphincter Electromyography. <i>Frontiers in Neurology</i> , 2020, 11, 1043.	1.1	10
443	Differential Circulating Levels of Naturally Occurring Antibody to α -Synuclein in Parkinson's Disease Dementia, Alzheimer's Disease, and Vascular Dementia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 571437.	1.7	6
444	Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological α -Synuclein in Parkinson's Disease Patients. <i>ACS Chemical Neuroscience</i> , 2020, 11, 4179-4190.	1.7	6
445	Extracellular Vesicles in Alzheimer's and Parkinson's Disease: Small Entities with Large Consequences. <i>Cells</i> , 2020, 9, 2485.	1.8	36
446	Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8666.	1.8	13
447	Parkinson's: A Disease of Aberrant Vesicle Trafficking. <i>Annual Review of Cell and Developmental Biology</i> , 2020, 36, 237-264.	4.0	54
448	The role of natural killer cells in Parkinson's disease. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1517-1525.	3.2	42
449	Fluid Biomarkers for Synaptic Dysfunction and Loss. <i>Biomarker Insights</i> , 2020, 15, 117727192095031.	1.0	74
450	Decreased plasma α -synuclein in idiopathic Parkinson's disease patients after adjusting hemolysis factor. <i>Molecular and Cellular Toxicology</i> , 2020, 16, 477-484.	0.8	6
451	Molecular events underlying the cell-to-cell transmission of α -synuclein. <i>FEBS Journal</i> , 2021, 288, 6593-6602.	2.2	27
452	Insights Into the Proteomic Profiling of Extracellular Vesicles for the Identification of Early Biomarkers of Neurodegeneration. <i>Frontiers in Neurology</i> , 2020, 11, 580030.	1.1	29
453	Salivary alpha-synuclein (total and oligomeric form): potential biomarkers in Parkinson's disease. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2020, 56, .	0.4	17

#	ARTICLE	IF	CITATIONS
454	An intact membrane is essential for small extracellular vesicle-induced modulation of α -synuclein fibrillization. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12034.	5.5	7
455	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3523.	1.8	24
456	Molecular Mechanism for the Suppression of Alpha Synuclein Membrane Toxicity by an Unconventional Extracellular Chaperone. <i>Journal of the American Chemical Society</i> , 2020, 142, 9686-9699.	6.6	15
457	Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization. <i>Diagnostics</i> , 2020, 10, 339.	1.3	20
458	Inhibition of aggregation and toxicity of α -synuclein in the presence of copper by an N-methylated peptide. <i>Journal of Molecular Structure</i> , 2020, 1211, 128079.	1.8	3
459	Soluble endogenous oligomeric α -synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1-28.	1.5	40
460	The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease. <i>Biomolecules</i> , 2020, 10, 912.	1.8	18
461	Potential sources of interference with the highly sensitive detection and quantification of α -synuclein seeds by qRT-PCR. <i>FEBS Open Bio</i> , 2020, 10, 883-893.	1.0	6
462	Serum α -synuclein and IL-1 β are increased and correlated with measures of disease severity in children with epilepsy: potential prognostic biomarkers?. <i>BMC Neurology</i> , 2020, 20, 85.	0.8	27
463	Protein transmission in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2020, 16, 199-212.	4.9	330
464	Age-Specific Retinal and Cerebral Immunodetection of Amyloid- β Plaques and Oligomers in a Rodent Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1135-1150.	1.2	26
465	Erythrocytic α -synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis. <i>Acta Neuropathologica Communications</i> , 2020, 8, 102.	2.4	26
466	A nanospherical conjugated microporous polymer-graphene nanosheets modified molecularly imprinted electrochemical sensor for high sensitivity detection of α -Synuclein. <i>Journal of Electroanalytical Chemistry</i> , 2020, 862, 113994.	1.9	42
467	Electrochemiluminescent aptamer-sensor for alpha synuclein oligomer based on a metal-organic framework. <i>Analyst</i> , 2020, 145, 2159-2167.	1.7	25
468	Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 35-40.	1.1	12
469	Low serum α -SYNUCLEIN and oligomer α -SYNUCLEIN levels in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 350, 577432.	1.1	4
470	Alpha-Synuclein in the Blood of Mice in a Neurotoxic Model of Parkinson's Disease. <i>Neurochemical Journal</i> , 2021, 15, 18-23.	0.2	0
471	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. , 2021, , 291-310.		0

#	ARTICLE	IF	CITATIONS
472	The role of astrocytes in prion-like mechanisms of neurodegeneration. <i>Brain</i> , 2022, 145, 17-26.	3.7	10
473	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. <i>Nature Reviews Chemistry</i> , 2021, 5, 277-294.	13.8	56
474	Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. <i>Cells</i> , 2021, 10, 375.	1.8	54
475	Biomarkers and the Role of α -Synuclein in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 645996.	1.7	13
476	Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 46.	2.4	14
477	Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3960.	1.8	0
478	Stress Response Is the Main Trigger of Sporadic Amyloidoses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4092.	1.8	5
479	Neurons and Glia Interplay in α -Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4994.	1.8	28
480	α -Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2508-2518.	2.2	47
481	Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice. <i>Neurobiology of Aging</i> , 2021, 101, 207-220.	1.5	11
482	Cooperative inhibition of SNARE-mediated vesicle fusion by α -synuclein monomers and oligomers. <i>Scientific Reports</i> , 2021, 11, 10955.	1.6	20
483	Desulfovibrio Bacteria Are Associated With Parkinson's Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 652617.	1.8	82
484	Photoelectrochemical Sensing of α -Synuclein Based on a AuNPs/Graphdiyne-Modified Electrode Coupled with a Nanoprobe. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 26515-26521.	4.0	16
485	Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity. <i>Molecules</i> , 2021, 26, 3736.	1.7	19
486	Distinct responses of human peripheral blood cells to different misfolded protein oligomers. <i>Immunology</i> , 2021, 164, 358-371.	2.0	7
487	Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6517.	1.8	38
488	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1761-1772.	1.5	15
489	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	2.5	74

#	ARTICLE	IF	CITATIONS
490	NGHIÃŠN Cá»“U Ná»’NG Äá»~ DOPAMIN CÃ™NG CÃC CHÁ°T CHUYá»,N HÃ“A Cá» A DOPAMIN TRONG Dá»ŠCH NÃfO Tá» Y VÃ€ Má»† Vá»šl Má»†T Sá»•Blá»,U HlÁ»†N LÃ,M SÃ€NG á»ž Bá»†NH NHÃ,N Má»°C Bá»†NH PARKINSON. Y Hoc Viet Nam, 2021, 502, .	0.0	0
491	Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic Î±-synuclein oligomers in Parkinsonâ€™s disease. Glycoconjugate Journal, 2022, 39, 1-11.	1.4	20
492	Alpha-Synuclein as a Biomarker of Parkinsonâ€™s Disease: Good, but Not Good Enough. Frontiers in Aging Neuroscience, 2021, 13, 702639.	1.7	55
493	Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinsonâ€™s disease. Brain, 2022, 145, 632-643.	3.7	20
494	Diagnosis of Parkinson Disease: Imaging and Non-Imaging Techniques. Series in Bioengineering, 2022, , 61-78.	0.3	0
495	Investigation of Î±-Synuclein Species in Plasma Exosomes and the Oligomeric and Phosphorylated Î±-Synuclein as Potential Peripheral Biomarker of Parkinsonâ€™s Disease. Neuroscience, 2021, 469, 79-90.	1.1	35
496	Structural and Functional Insights into Î±-Synuclein Fibril Polymorphism. Biomolecules, 2021, 11, 1419.	1.8	39
498	Cerebrospinal Fluid Î±-Synuclein Species in Cognitive and Movements Disorders. Brain Sciences, 2021, 11, 119.	1.1	14
500	Nanoparticle-based colorimetric sensors to detect neurodegenerative disease biomarkers. Biomaterials Science, 2021, 9, 6983-7007.	2.6	5
502	Preparation and Structural Characterization of Pre-fibrillar Assemblies of Amyloidogenic Proteins. , 2012, , 61-102.		1
503	The Use of Biomarkers for Prediction and Prevention of Alzheimerâ€™s and Parkinsonâ€™s Diseases. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 95-140.	0.6	2
504	Proteasome activity regulated by charged gold nanoclusters: Implications for neurodegenerative diseases. Nano Today, 2020, 35, 100933.	6.2	10
505	Discriminating Î±-synuclein strains in Parkinsonâ€™s disease and multiple system atrophy. Nature, 2020, 578, 273-277.	13.7	479
508	Metabolomic Profiling in LRRK2-Related Parkinson's Disease. PLoS ONE, 2009, 4, e7551.	1.1	142
509	Glial Innate Immunity Generated by Non-Aggregated Alpha-Synuclein in Mouse: Differences between Wild-type and Parkinson's Disease-Linked Mutants. PLoS ONE, 2010, 5, e13481.	1.1	89
510	Î±-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients. PLoS ONE, 2011, 6, e18513.	1.1	146
511	PrPSc-Specific Antibodies with the Ability to Immunodetect Prion Oligomers. PLoS ONE, 2011, 6, e19998.	1.1	21
512	The AAA-ATPase VPS4 Regulates Extracellular Secretion and Lysosomal Targeting of Î±-Synuclein. PLoS ONE, 2011, 6, e29460.	1.1	120

#	ARTICLE	IF	CITATIONS
513	Triggering of Inflammasome by Aggregated α -Synuclein, an Inflammatory Response in Synucleinopathies. PLoS ONE, 2013, 8, e55375.	1.1	465
514	Preconditioning of Microglia by α -Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation. PLoS ONE, 2013, 8, e79160.	1.1	92
515	Decrease in Plasma Levels of α -Synuclein Is Evident in Patients with Parkinson's Disease after Elimination of Heterophilic Antibody Interference. PLoS ONE, 2015, 10, e0123162.	1.1	54
516	Emerging candidate biomarkers for Parkinson's disease: a review. , 2014, 5, 27-34.		26
517	Detection of mis-folded protein aggregates from a clinical perspective. Journal of Clinical and Translational Research, 2016, 2, .	0.3	2
518	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α -syn) oligomerization and secretion. Aging, 2017, 9, 1677-1697.	1.4	7
519	Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease. Oncotarget, 2016, 7, 54215-54227.	0.8	30
520	Aging and Neuroinflammatory Disorders: New Biomarkers and Therapeutic Targets. Current Pharmaceutical Design, 2019, 25, 4168-4174.	0.9	15
521	Drug Targets from Genetics: Alpha-Synuclein. CNS and Neurological Disorders - Drug Targets, 2011, 10, 712-723.	0.8	9
522	Detection and Assessment of α -Synuclein Oligomers in the Urine of Parkinson's Disease Patients. Journal of Parkinson's Disease, 2020, 10, 981-991.	1.5	22
523	Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's		

#	ARTICLE	IF	CITATIONS
531	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. <i>Pharmacological Reviews</i> , 2021, 73, 1204-1268.	7.1	11
533	Protein seeding in Alzheimer's disease and Parkinson's disease: Similarities and differences. <i>World Journal of Neurology</i> , 2014, 4, 23.	0.6	0
534	Laboratory Biomarkers of Early Diagnosis of Parkinson's Disease. <i>International Neurological Journal</i> , 2016, .	0.2	2
537	Early stages of Parkinson's disease: aspects of the diagnosis and therapy. <i>Meditinskiy Sovet</i> , 2019, , 61-70.	0.1	0
539	Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. <i>Metabolic Brain Disease</i> , 2022, 37, 67-104.	1.4	24
540	Bacteriophage Therapies Targets Multiple Diseases Caused by Protein Misfolding. , 2020, , 385-401.		0
541	Synuclein in neurodegeneration. <i>Advances in Clinical Chemistry</i> , 2021, 103, 97-134.	1.8	10
543	Detection of misfolded protein aggregates from a clinical perspective. <i>Journal of Clinical and Translational Research</i> , 2016, 2, 11-26.	0.3	3
544	Alpha-synuclein oligomerization increases its effect on promoting NMDA receptor internalization. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 87-100.	0.5	2
545	What about biomarkers for parkinson's disease?. <i>Innovations in Clinical Neuroscience</i> , 2021, 18, 9-10.	0.1	0
546	Spreading of alpha-synuclein pathology from the gut to the brain in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, 2, 155-191.	0.1	0
547	Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson's disease: A systematic review of proteomics studies. <i>Ageing Research Reviews</i> , 2022, 73, 101514.	5.0	7
548	Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors. <i>International Review of Movement Disorders</i> , 2021, 2, 1-63.	0.1	0
549	A Protein Corona Modulates Interactions of α -Synuclein with Nanoparticles and Alters the Rates of the Microscopic Steps of Amyloid Formation. <i>ACS Nano</i> , 2022, 16, 1102-1118.	7.3	9
550	Split-type cascaded silver etching for α -syn-super off-PEC-EC dual-mode immunosensing of α -SynO. <i>Sensors and Actuators B: Chemical</i> , 2022, 358, 131449.	4.0	8
551	Salivary α -synuclein as a potential fluid biomarker in Parkinson's disease: A systematic review and meta-analysis. <i>Ageing Medicine (Milton (N S W))</i> , 2022, 5, 53-62.	0.9	8
552	Association of plasma α -synuclein with cardiac 123I-MIBG scintigraphy in early Parkinson's disease. <i>Neuroscience Letters</i> , 2022, 770, 136399.	1.0	5
553	Erythrocytic α -Synuclein Species for Parkinson's Disease Diagnosis and the Correlations With Clinical Characteristics. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 827493.	1.7	8

#	ARTICLE	IF	CITATIONS
554	Improvement of non-motor and motor behavioral alterations associated with Parkinson-like disease in <i>Drosophila melanogaster</i> : Comparative effects of treatments with hesperidin and L-dopa. <i>NeuroToxicology</i> , 2022, 89, 174-183.	1.4	8
555	Detection of neuron-derived pathological $\hat{\pm}$ -synuclein in blood. <i>Brain</i> , 2022, 145, 3058-3071.	3.7	82
556	$\hat{\pm}$ -Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinsonâ€™s disease. <i>Journal of Neuroinflammation</i> , 2022, 19, 53.	3.1	17
557	Hydrogen Sulfide Produced by Gut Bacteria May Induce Parkinsonâ€™s Disease. <i>Cells</i> , 2022, 11, 978.	1.8	30
558	Phosphorylated $\hat{\pm}$ -synuclein in diluted human serum as a biomarker for Parkinson's disease. <i>Biomedical Journal</i> , 2022, 45, 914-922.	1.4	8
559	Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview. <i>Current Pharmaceutical Design</i> , 2022, 28, .	0.9	4
560	Blood-based biomarker in Parkinsonâ€™s disease: potential for future applications in clinical research and practice. <i>Journal of Neural Transmission</i> , 2022, 129, 1201-1217.	1.4	23
567	Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation. <i>Biomolecules</i> , 2022, 12, 655.	1.8	16
568	Saliva is a Good Candidate to be the New Gold-Standard Sample for Neurodegenerative Diseases. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-5.	1.2	4
569	New Insights and Implications of Natural Killer Cells in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, S83-S92.	1.5	10
570	Managing Bipolar Disease Complicated with Psychosis in Conjunction with Polypharmacy, Parkinsonâ€™s Disease, and Multiple Comorbidities. <i>Case Reports in Psychiatry</i> , 2022, 2022, 1-7.	0.2	0
571	Lewy Body-Associated Proteins A-Synuclein (α -syn) as a Plasma-Based Biomarker for Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	6
572	A facile and effective immunoassay for sensitive detection of phosphorylated tau: The role of flower-shaped TiO ₂ in specificity and signal amplification. <i>Sensors and Actuators B: Chemical</i> , 2022, 366, 132015.	4.0	7
573	Receptor-Dependent Endocytosis Mediates $\hat{\pm}$ -Synuclein Oligomer Transport Into Red Blood Cells. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	1
574	Microparticle immunocapture assay for quantitation of protein multimer amount and size. <i>Cell Reports Methods</i> , 2022, 2, 100214.	1.4	2
575	Electrochemical Aptasensors for Parkinsonâ€™s Disease Biomarkers Detection. <i>Current Medicinal Chemistry</i> , 2022, 29, 5795-5814.	1.2	2
576	The Common Cellular Events in the Neurodegenerative Diseases and the Associated Role of Endoplasmic Reticulum Stress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5894.	1.8	15
577	Pathogenic Impact of $\hat{\pm}$ -Synuclein Phosphorylation and Its Kinases in $\hat{\pm}$ -Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6216.	1.8	25

#	ARTICLE	IF	CITATIONS
580	Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 5762-5786.	1.8	11
581	The Roles of ATP13A2 Gene Mutations Leading to Abnormal Aggregation of α -Synuclein in Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	7
582	Exosomes in Alpha-Synucleinopathies: Propagators of Pathology or Potential Candidates for Nanotherapeutics?. <i>Biomolecules</i> , 2022, 12, 957.	1.8	8
583	Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 6386-6394.	1.8	10
584	Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	41
585	Spreading of alpha-synuclein between different cell types. <i>Behavioural Brain Research</i> , 2023, 436, 114059.	1.2	6
586	α -Glycerolphosphoryl ethanolamine protects human hippocampal neurons from ageing-induced cellular alterations. <i>European Journal of Neuroscience</i> , 2022, 56, 4514-4528.	1.2	1
587	The Role of α -Synuclein in SNARE-mediated Synaptic Vesicle Fusion. <i>Journal of Molecular Biology</i> , 2023, 435, 167775.	2.0	14
588	The Role of Amyloid- β , Tau, and α -Synuclein Proteins as Putative Blood Biomarkers in Patients with Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 1039-1049.	1.2	1
589	Disease-Associated α -Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage. <i>Neurology</i> , 2022, 99, .	1.5	20
590	Novel pathophysiological roles of α -synuclein in age-related vascular endothelial dysfunction. <i>FASEB Journal</i> , 2022, 36, .	0.2	3
591	Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons. <i>Biomedicines</i> , 2022, 10, 2278.	1.4	4
592	Clinical application of prion-like seeding in α -synucleinopathies: Early and non-invasive diagnosis and therapeutic development. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	0
593	Plasma-derived phosphoglycerate mutase 5 as a biomarker for Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	0
594	Toxic Misfolded Transthyretin Oligomers with Different Molecular Conformations Formed through Distinct Oligomerization Pathways. <i>Biochemistry</i> , 2022, 61, 2358-2365.	1.2	4
595	Global, in situ analysis of the structural proteome in individuals with Parkinson's disease to identify a new class of biomarker. <i>Nature Structural and Molecular Biology</i> , 2022, 29, 978-989.	3.6	16
596	Monitoring α -synuclein aggregation. <i>Neurobiology of Disease</i> , 2023, 176, 105966.	2.1	12
597	DNAzyme-driven tripedal DNA walker mediated signal-on and label-free for electrochemical detection of α -synuclein oligomers. <i>Sensors and Actuators B: Chemical</i> , 2023, 378, 133150.	4.0	7

#	ARTICLE	IF	CITATIONS
598	Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14630.	1.8	6
599	Unravelling the genetic links between Parkinson's disease and lung cancer. <i>Biological Chemistry</i> , 2023, 404, 551-567.	1.2	1
600	Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 789.	1.8	0
601	Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma α -Synuclein and Parkinson's Disease. <i>Molecular Neurobiology</i> , 0, , .	1.9	0
602	α -synuclein as a promising biomarker for developing diagnostic tools against neurodegenerative synucleinopathy disorders. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 159, 116922.	5.8	3
604	The Role of Proteolysis in Amyloidosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 699.	1.8	5
605	Low Levels of Adenosine and GDNF Are Potential Risk Factors for Parkinson's Disease with Sleep Disorders. <i>Brain Sciences</i> , 2023, 13, 200.	1.1	8
606	Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons. <i>Frontiers in Cellular Neuroscience</i> , 0, 17, .	1.8	3
607	Deep brain stimulation improves central nervous system inflammation in Parkinson's disease: Evidence and perspectives. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 2177-2185.	1.9	3
609	Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease. <i>Biomedicines</i> , 2023, 11, 728.	1.4	6
626	Diagnostic Biomarkers of Parkinson's Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2023, , 64-80.	0.1	0
628	Electrochemical biosensor-based detection assays for early diagnosis of neurodegenerative disorders. , 2024, , 155-177.		0